Sugar-lowering drugs for type 2 Diabetes Mellitus and Metabolic Syndrome Review of cassical and new compounds: Part-I

dc.contributor.authorVieira, Raquel
dc.contributor.authorSouto, Selma B.
dc.contributor.authorSánchez-López, E. (Elena)
dc.contributor.authorLópez-Machado, Ana
dc.contributor.authorSeverino, Patrícia
dc.contributor.authorJose, Sajan
dc.contributor.authorSantini, Antonello
dc.contributor.authorFortiuna, Ana
dc.contributor.authorGarcía López, María Luisa
dc.contributor.authorSilva, Amélia M.
dc.contributor.authorSouto, Eliana B.
dc.date.accessioned2020-06-19T14:32:20Z
dc.date.available2020-06-19T14:32:20Z
dc.date.issued2019-10-10
dc.date.updated2020-06-19T14:32:20Z
dc.description.abstractDiabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia together with disturbances in the metabolism of carbohydrates, proteins and fat, which in general results from an insulin availability and need imbalance. In a great number of patients, marketed anti-glycemic agents have shown poor effectiveness in maintaining a long-term glycemic control, thus being associated with severe adverse effects and leading to an emerging interest in natural compounds (e.g., essential oils and other secondary plant metabolites, namely, flavonoid-rich compounds) as a novel approach for prevention, management and/or treatment of either non-insulin-dependent diabetes mellitus (T2DM, type 2 DM) and/or Metabolic Syndrome (MS). In this review, some of these promising glucose-lowering agents will be comprehensively discussed
dc.format.extent31 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec701302
dc.identifier.issn1424-8247
dc.identifier.pmid31658729
dc.identifier.urihttps://hdl.handle.net/2445/166338
dc.language.isoeng
dc.publisherMDPI
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/ph12040152
dc.relation.ispartofPharmaceuticals, 2019, vol. 12, num. 4, p. 152
dc.relation.urihttps://doi.org/10.3390/ph12040152
dc.rightscc-by (c) Vieira, Raquel et al., 2019
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
dc.subject.classificationDiabetis no-insulinodependent
dc.subject.classificationSíndrome metabòlica
dc.subject.classificationFitoteràpia
dc.subject.classificationFarmacologia
dc.subject.classificationGlucèmia
dc.subject.otherNon-insulin-dependent diabetes
dc.subject.otherMetabolic syndrome
dc.subject.otherPhytotherapy
dc.subject.otherPharmacology
dc.subject.otherBlood sugar
dc.titleSugar-lowering drugs for type 2 Diabetes Mellitus and Metabolic Syndrome Review of cassical and new compounds: Part-I
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
701302.pdf
Mida:
1.18 MB
Format:
Adobe Portable Document Format